Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada

PHASE3CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

May 20, 2012

Primary Completion Date

January 19, 2018

Study Completion Date

January 19, 2018

Conditions
Duchenne Muscular DystrophyBecker Muscular DystrophyDystrophinopathy
Interventions
DRUG

Ataluren

Oral powder for suspension

Trial Locations (21)

Unknown

Royal Children's Hospital, Parkville

Institute For Neuromuscular Research, The Children's Hospital at Westmead, Westmead

University Hospital KU Leuven, Leuven

Alberta Children's Hospital, Calgary

British Columbia Children's Hospital, Vancouver

Children's Hospital of Western Ontario, London

Hôpital d'Enfants CHU Timone, Marseille

Laboratoire d'Exploration Fonctionnelles, Nantes

Groupe Hospitalier La Pitie-Salpetriere, Paris

University of Essen - Clinic for Children, Essen

University Hospital, Freiburg im Breisgau

Hadassah Medical Center, Hebrew University Hospital, Jerusalem

Ospedale Maggiore Policlinico in Milan, Milan

Ospedale Pediatrico Bambino Gesu, Rome

U.O. Complessa di Neuropsichiatria Infantile, Rome

Hospital Sant Joan de déu, Barcelona

Hospital Universitari La Fe, Valencia

Queen Silvia Children's Hospital, Gothenburg

Astrid Lindgren Pediatric Hospital, Stockholm

Great Ormond Street Hospital, London

University of Newcastle Institute of Human Genetics, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY